Lundbeck A/S has announced positive results from clinical trials testing the efficacy of a new compound Lu AA24530 for the treatment of major depressive disorder (MDD).
A six-week study compared the efficacy of three doses of Lu AA24530, 5, 10 and 20mg, to that of placebo in terms of change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS). Lu AA24530 consistently produced statistically significant improvements on the primary efficacy endpoint and on key secondary endpoints.
This trial also demonstrated that Lu AA24530 was well tolerated with low drop-out rates due to serious adverse events.
Lundbeck executive vice-president and head of drug development Anders Gersel Pedersen said that these findings demonstrate the potential value of Lu AA24530.
“We are pleased with the combination of efficacy and good tolerability for Lu AA24530 which clearly supports the development of the compound as a future treatment option for physicians and patients,” Pedersen said.
The active reference compound duloxetine, which was included as an active reference compound in the trial, also produced a significant improvement compared to placebo, thereby validating the study.